SBT5.6 Antibody

Potential Nomenclature Confusion

The search results extensively discuss SBT5.2 (a plant subtilase) and SBT-100 (a single-domain antibody targeting KRAS/STAT3) but contain no references to "SBT5.6." Key findings from related terms include:

Typographical Error

• "SBT5.6" may be a misspelling of SBT5.2, a well-characterized subtilase with roles in plant-pathogen interactions ([Source 3] ).

• Alternatively, it could refer to SBT-100, a therapeutic antibody documented in oncology research ([Source 1] ).

Obscure or Proprietary Compound

• If "SBT5.6" exists, it may be an unpublished/internal designation from a private biotech entity. No public data supports this.

Recommendations for Further Inquiry

1. Verify Nomenclature: Confirm the correct spelling or alternative identifiers (e.g., UniProt ID, CAS number).

2. Expand Search Scope:

   • Query specialized databases: ClinicalTrials.gov, Patentscope, or EMA/FDA filings.

   • Consult preprint platforms: bioRxiv, arXiv.

3. Contact Authors: Reach out to researchers working on SBT5.2 (e.g., Beritza et al., Chen et al.) for clarification.

Key Functions of SBT5.2

• Immune Modulation: Degrades bacterial elicitors (e.g., flg22, csp22) to suppress excessive immune activation .

• Antibody Processing: Cleaves IgG antibodies in plant apoplasts, affecting therapeutic yields .

Therapeutic Potential of SBT-100

• Targets: KRAS (mutation-driven cancers) and STAT3 (autoimmune/neurodegenerative diseases) .

• Delivery: Crosses blood-brain and blood-retina barriers with rapid serum clearance (1–2 hr half-life) .